Adam Berger, MD, FACS, Receives Sidney Kimmel Cancer Center Achievement in Clinical Research Award


Dr. Kevin Kelly and Dr. Adam Berger

Adam Berger, MD, FACS (right), receiving his award from Kevin Kelly, DO.

Congratulations to Adam Berger, MD, FACS, Vice Chair for Clinical Research, who recently received the “Achievement in Clinical Research Award” at the 2018 Sidney Kimmel Cancer Center (SKCC) Member Retreat, held at Citizens Bank Park in Philadelphia. The award was presented to Berger by Kevin Kelly, DO, Associate Director of Clinical Research and Leader of the Prostate Cancer Program at the SKCC.

Berger is also a Professor of Surgery at Thomas Jefferson University and serves as the Chief of the Section of Surgical Oncology in the Department of Surgery. He has a strong clinical focus in melanoma and breast cancer. Berger has been instrumental in developing the clinical research portfolio and translational research components of the Breast Cancer Program and Cutaneous Melanoma group.

His interests include oncology clinical trials, the development of clinical databases, and the prospective evaluation of clinicopathologic prognostic factors for malignancies. He is currently the surgical PI on RTOG 0848, the adjuvant pancreatic cancer trial, and has served on the AAS Education, Leadership, and Membership Committees, the Executive Council of the Association for Academic Surgery, and the Program Committee of the Society of Surgical Oncology. In addition to his busy clinical and research activities, Berger serves as the Chair of the Protocol Review Committee (PRC) at the SKCC, revamping and streamlining the committee.

The SKCC Achievement in Clinical Research Award is given to an individual who has shown outstanding dedication and service for facilitating novel therapies to patients; discovering innovative research strategies; and serving as a role model for junior clinical researchers.

“I am very honored to receive this award in acknowledgement of my contributions to clinical research in the cancer center,” Berger said. “The work that we have done to improve enrollment of patients to clinical trials in both breast cancer and melanoma has definitely helped our patients.”